atossa therapeutics, inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the united states. the company's lead program is the development of endoxifen, an active metabolite of tamoxifen which is in phase ii studies to treat and prevent breast cancer. it is also developing intraductal microcatheter technology to target the delivery of therapies, including fulvestrant, immunotherapies, and chimeric antigen receptor t-cell therapies, directly to the site of breast cancer. the company was formerly known as atossa genetics inc. and changed its name to atossa therapeutics, inc. in january 2020. atossa therapeutics, inc. was founded in 2009 and is headquartered in seattle, washington.
Company profile
Ticker
ATOS
Exchange
Website
CEO
Steven Quay
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ATOSSA GENETICS INC
SEC CIK
Corporate docs
Subsidiaries
Atossa Genetics UK Ltd. • Atossa Genetics AUS Pty Ltd. ...
IRS number
264753208
ATOS stock data
Latest filings (excl ownership)
8-K/A
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
1 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
8-K
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
1 Apr 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
18 Mar 24
8-K
Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors
12 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
13 Nov 23
8-K
Departure of Directors or Certain Officers
9 Nov 23
8-K
Departure of Directors or Certain Officers
6 Oct 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
28 Sep 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 94.14 mm | 94.14 mm | 94.14 mm | 94.14 mm | 94.14 mm | 94.14 mm |
Cash burn (monthly) | 1.79 mm | 1.94 mm | 2.49 mm | 2.71 mm | 1.29 mm | 1.66 mm |
Cash used (since last report) | 12.21 mm | 13.29 mm | 17.02 mm | 18.53 mm | 8.85 mm | 11.33 mm |
Cash remaining | 81.93 mm | 80.85 mm | 77.13 mm | 75.61 mm | 85.29 mm | 82.81 mm |
Runway (months of cash) | 45.9 | 41.6 | 31.0 | 27.9 | 65.9 | 50.0 |
Institutional ownership, Q2 2023
20.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 52 |
Opened positions | 10 |
Closed positions | 4 |
Increased positions | 10 |
Reduced positions | 13 |
13F shares | Current |
---|---|
Total value | 18.25 bn |
Total shares | 25.99 mm |
Total puts | 27.90 k |
Total calls | 258.20 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
CVI Investments | 7.76 mm | $0.00 |
Vanguard | 5.68 mm | $7.15 bn |
BLK Blackrock | 2.90 mm | $3.65 bn |
Intracoastal Capital | 2.25 mm | $1.94 mm |
Laurion Capital Management | 2.23 mm | $2.80 bn |
Geode Capital Management | 1.11 mm | $1.40 bn |
Renaissance Technologies | 1.07 mm | $1.35 mm |
STT State Street | 436.27 k | $549.70 mm |
Susquehanna International | 373.03 k | $470.02 mm |
Millennium Management | 316.41 k | $398.67 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
10 Apr 24 | Jonathan Finn | Common Stock | Buy | Acquire P | No | No | 1.77 | 25,000 | 44.25 k | 25,000 |
9 Mar 24 | Tessa Cigler | Stock Option Common Stock | Grant | Acquire A | No | No | 1.09 | 20,834 | 22.71 k | 20,834 |
15 Nov 23 | Jonathan Finn | Stock Option Common Stock | Grant | Acquire A | No | No | 0.65 | 62,500 | 40.63 k | 62,500 |
News
HC Wainwright & Co. Reiterates Buy on Atossa Therapeutics, Maintains $4 Price Target
16 Apr 24
Atossa Therapeutics And Quantum Leap Healthcare Initiates I-SPY 2 Clinical Trial To Evaluate (Z)-Endoxifen In Combination With Abemaciclib In Women With ER+/HER2- Breast Cancer
15 Apr 24
Atossa Therapeutics Presents Data From 40mg Cohort Of Phase 2 EVANGELINE Clinical Trial
9 Apr 24
HC Wainwright & Co. Maintains Buy on Atossa Therapeutics, Maintains $4 Price Target
2 Apr 24
HC Wainwright & Co. Initiates Coverage On Atossa Therapeutics with Buy Rating, Announces Price Target of $4
12 Feb 24
Press releases
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer
15 Apr 24
Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference
11 Apr 24
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen
9 Apr 24
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
1 Apr 24
Thinking about buying stock in Cardiff Oncology, BIOLASE, Akebia Therapeutics, Astera Labs, or Atossa Therapeutics?
26 Mar 24